Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | TACR1 | P25103 | 5/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | AGER | Q15109 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8194993 | 0.76 | EPHX1 (0.43) | TSHRCYP1A2CYP2D6 | |
| SCHEMBL29184246 | 0.75 | CA1 (0.56) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL19496903 | 0.75 | CA1 (0.61) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL21848157 | 0.73 | TSHR (0.67) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL23674403 | 0.72 | CA1 (0.53) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL6379461 | 0.72 | CA1 (0.53) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL3665423 | 0.72 | TSHR (0.52) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL10744312 | 0.72 | TSHR (0.52) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL17789130 | 0.72 | TSHR (0.52) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL10463016 | 0.71 | TSHR (0.56) | TSHRCA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122627-B2 | Lactam inhibitors of Hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| US-20040171556-A1 | Methods for inhibiting proteasome | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-02 | — | — | US | disclosed |
| WO-2004064755-A2 | METHODS FOR INHIBITING PROTEASOME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20030008828-A1 | Diagnostic kits; for therapy of viral infection; as assat standard or reagent | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008828-A1 | Diagnostic kits; for therapy of viral infection; as assat standard or reagent | PRSS3, PRSS1, PREP | TSHR 4580/4885CA1 1492/4885CA2 1416/4885 |
| US-20040171556-A1 | Methods for inhibiting proteasome | PSMB1, PSMB11, PSMG3 | TSHR 4048/4885CA1 2793/4885CA2 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.